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Abstract The gene responsible for cystic fibrosis encodes a
membrane protein ^ the 1480-residue cystic fibrosis transmem-
brane conductance regulator (CFTR) ^ in which membrane-
based CF-phenotypic mutants alter pore structure and/or impair
ion transport. We report the preparation in milligram quantities
and conformational characterization of a polypeptide comprised
of CFTR transmembrane (TM) segments 3^4, a putative ‘helical
hairpin’ portion of the CFTR TM1^6 domain. The TM segment
3^4 of CFTR was expressed in E. coli as a fusion protein linked
to the C-terminus of His-tagged thioredoxin. Nickel chelate
affinity chromatography, followed by release from the carrier by
digestion with thrombin protease, gave free CFTR(TM3^4).
Monitoring of the folding properties and conformational state(s)
of the TM3^4 polypeptide using circular dichroism spectroscopy
indicated a partial K-helical conformation in aqueous buffer, with
up to 30% increase in K-helical content observed in membrane-
mimetic environments.
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1. Introduction
Cystic ¢brosis (CF) is an autosomal recessive genetic dis-
ease a¡ecting the epithelium, especially the airways, the pan-
creatic ducts, the sudoriparous glands and bile ducts [1]. The
gene responsible for CF has been isolated and predicted to
encode a membrane protein ^ the cystic ¢brosis transmem-
brane conductance regulator (CFTR) [2,3]. CFTR is a mem-
ber of the ATP-binding cassette protein superfamily and con-
sists of two repeated elements, each comprising six putative
membrane-spanning segments and a nucleotide-binding do-
main. The two repeats are separated by a large polar ‘R do-
main’ containing multiple potential phosphorylation sites [4].
While the most well-characterized CF defect in CFTR is lo-
calized to the ¢rst nucleotide-binding domain residue
(vPhe508), many mutations in the ¢rst transmembrane (TM)
domain (TM segments 1^6) are associated with CF disease [5^
7]; CF-phenotypic mutants in TM segments 3 and 4 are
shown in Fig. 1. Unlike mutant vPhe508 which is misprocessed
and fails to tra⁄c to the apical cell membrane, these TM
domain mutants are of particular interest because they are
correctly processed and delivered to the cell membrane. How-
ever, while certain TM mutations dramatically impair the
chloride channel function of CFTR [7], the manner through
which various mutants alter the CFTR pore structure or the
channel e⁄ciency remains to be characterized on the molec-
ular level.
The cytoplasmic domains of the CFTR have been charac-
terized to some extent [8^12], but comparatively little is
known about the transmembrane domains, largely because
of the low yields and insoluble aggregation (inclusion body)
e¡ects which traditionally accompany the handling of hydro-
phobic proteins. Solid-phase chemical synthesis is the method
of choice for single CFTR segments [13,14], but preparation
of multi-spanning hydrophobic segments presents a challenge
suited for the techniques of molecular biology. As an initial
step in the structural characterization of wild-type and mutant
CFTR proteins, we describe here the milligram-level expres-
sion in E. coli of double transmembrane segments of CFTR
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Fig. 1. Top: Schematized domain structure predicted for the cystic
¢brosis transmembrane conductance regulator (CFTR) protein. M1^
M6, M7^M12, membrane domains; NBDI, II, nucleotide binding
domains; R, regulatory domain. The rectangular box delineates the
transmembrane segments 3 and 4 (TM3^4) studied in the present
work. After Riordan et al. [2]. Bottom: Distribution of mutations
phenotypic for cystic ¢brosis in CFTR TM segments 3 and 4. X,
stop codon. Data taken from the CF Genetic Analysis Consortium,
1995.
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(‘helical hairpins’) as a fusion protein with thioredoxin. Our
studies include optimization of protein expression and puri¢-
cation, successful enzymatic cleavage of the CFTR segments
from the thioredoxin carrier, and initial structural character-
ization of CFTR TM3^4 segments.
2. Materials and methods
Chemicals and reagents were purchased from Sigma. Enzymes were
from New England Biolabs; enterokinase and thrombin proteinase
were from Novagen. SDS mini-gels were obtained from Novex. Bac-
terial strains were obtained from Novagen: E. coli strain DH5a was
used for cloning; E. coli BL21(DE3) was used in expression studies.
2.1. Construction of expression vectors
Subcloning and transformation steps of E. coli were carried out
using standard techniques [15]. The polymerase chain reaction
(PCR) was used to prepare the cDNA fragments of CFTR TM3^4.
A forward primer 5P-GCACCATGGGACTTGCATTGGCAC-3P
(containing an NcoI site) and a reverse primer 5P-CGTCT-
CGAGTCCCTAGCCCAGCCT-3P (containing an XhoI site) were de-
signed to de¢ne and amplify the CFTR coding sequence from base
711 to 858. PCR products of expected size were obtained and cloned
into the NcoI and XhoI sites of the pET32a(+) vector (Novagen) to
generate p32CFTM-P3 (Fig. 1). The recombinant plasmid with
CFTR(TM3^4) was sequenced to con¢rm the correct in-frame fusion
and the ¢delity of the PCR ampli¢cation.
2.2. Bacterial expression of TrxCFTR(TM3^4) fusion protein
The E. coli strain BL21(DE3) was transformed with the plasmid
generated above. Control bacteria were transformed with original
pET32a(+). Cultures were grown in Luria Broth medium at 37‡C until
OD600 reached 0.6^0.8, and induced with 0.1 mM IPTG at 25‡C. The
cultures were incubated for an additional 2^3 h. The cells were har-
vested by centrifugation at 4000Ug for 20 min. The cell pellet was
resuspended in 1/10 volume of lysis bu¡er A (20 mM Tris-HCl, pH
8.0, containing 500 mM NaCl, 5 mM imidazole, 0.1% Triton X-100),
or bu¡er B (same as bu¡er A but containing 1 M NaCl) and soni-
cated. The lysate was centrifuged at 16 000Ug for 40 min. The insolu-
ble protein fraction was redissolved in an equal volume of bu¡er A
containing 6 M guanidine hydrochloride. As a control, the vector
protein His-tag-thioredoxin-S-gag (but lacking the CFTR(TM3^4)
segment) was also prepared in parallel.
2.3. Puri¢cation of the TrxCFTR(TM3^4) fusion protein
All steps of puri¢cation were performed at room temperature.
TrxCFTR(TM3^4) fusion protein was puri¢ed from the lysis super-
natant by a⁄nity chromatography. His-bind resin (Novagen) was
packed into a column charged with 50 mM NiSO4 equilibrated with
lysis bu¡er. In typical experiments, crude extract containing the
TrxCFTR(TM3^4) fusion protein was mixed with 1/4 volume of pre-
pared resin. After allowing 30 min for equilibration at room temper-
ature, the solution was removed by ¢ltration and the resin beads were
eluted with bu¡er A containing a series of increasing imidazole con-
centrations. Analysis of the fractions was carried out on Tricine SDS-
PAGE and subsequently by Western blotting using an antibody
against thioredoxin. Gels were stained with Coomassie Blue R-250
or silver nitrate (the latter for cleaved proteins). Fractions containing
fusion proteins were pooled and dialyzed against 50 mM Tris-HCl
(pH 7.2) and 100 mM NaCl. Protein concentrations were determined
by combining the absorbance at 590 nm (Branford) and the densities
on the SDS-PAGE of the protein solutions using a standard curve
generated with BSA.
2.4. Proteolytic cleavage and puri¢cation of cleaved CFTR(TM3^4)
Puri¢ed TrxCFTR(TM3^4) fusion proteins (native) were digested
with enterokinase or thrombin proteinase according to the manufac-
turer’s speci¢cations. When the reaction was completed, components
of the reaction mixture were separated by SDS-PAGE [16] or a⁄nity
chromatography using Thio-resin [17] and S-resin [18]. The separa-
tions were carried out at ambient temperature.
2.5. Circular dichroism (CD) spectroscopy
Samples were prepared in aqueous solution containing 50 mM Tris-
HCl (pH 8.0) and 150 mM NaCl, with or without addition of 10 mM
lyso-phosphatidylcholine (LPC), lyso-phosphatidylglycerol (LPG), or
sodium dodecylsulfate (SDS). CD spectra were recorded using an 0.1
cm pathlength demountable cell in a Jasco-J-720A spectropolarimeter
at 25‡C, and at the physiological temperature of 37‡C. Each spectrum
was the average of four scans over the wavelength range of 190^250
nm with a step resolution of 0.2 nm.
3. Results and discussion
3.1. High-level expression of CFTR(TM3^4) as a soluble
fusion protein with thioredoxin
To express the CFTR(TM3^4) gene product in E. coli, the
corresponding fragments ^ which encompass CFTR trans-
membrane segments 3 and 4 ^ were inserted into the bacterial
expression vector pET32a(+). Fig. 2 presents the design of the
fusion construct. Expression of CFTR gene is under the con-
trol of a T7 promoter. The C-terminal coding region of the
thioredoxin gene was fused to the inserted CFTR(TM3^4)
coding sequence (53 aa), linked by an S-tag (15 aa) for en-
hancing solubility [17] and for detection of the target protein.
Between the fusion partner and CFTR(TM3^4), a cleavage
recognition sequence for enterokinase (EK), DDDDK, was
inserted adjacent to the N-terminus of CFTR(TM3^4). An-
other potential cleavage site ^ the protease recognition se-
quence for thrombin ^ was inserted such that it would allow
release CFTR(TM3^4) from thioredoxin with the CFTR poly-
peptide containing an N-terminal S-tag sequence. His-tags
located both upstream and downstream of CFTR(TM3^4)
segments were also incorporated to allow a one-step method
for protein puri¢cation by Ni-chelate chromatography [19] at
all stages of the preparation. Expression of recombinants was
carried out after transformation into E. coli strain
BL21(DE3). Control bacteria were transformed with the orig-
inal pET32a(+).
Fig. 3 illustrates the expression of TrxCFTR(TM3^4) from
its expression plasmid, which was capable of producing the
target protein with little di¡erence in levels at 25‡C or 37‡C.
The recombinants of TrxCFTR(TM3^4) from cells migrated
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Fig. 2. A: Construct p32CFTM-P3 designed for expression of the
TrxCFTR(TM3^4) fusion protein. Trx, His-tagged thioredoxin. The
cDNA fragment of CFTR(TM3^4) was synthesized by PCR and li-
gated into NcoI/XhoI sites of p32a(+). B: The linearized sequence of
the TrxCFTR(TM3^4) fusion protein. The two protease cleavage
sites are shown.
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as a band with an apparent molecular mass of 24 kDa, which
was absent in uninduced cells or induced cells without the
CFTR(TM3^4) insert (Fig. 3A). An immunologically recog-
nizable band was detected at same molecular mass upon per-
forming a Western blot using anti-thioredoxin (Fig. 3B). It
was estimated that the fusion protein accounted for approx-
imately 15^20% of total cell protein.
3.2. Solubility of expressed TrxCFTR(TM3^4)
The production of biologically-active proteins is often ham-
pered by formation of inclusion bodies [20]. Preliminary ex-
periments to optimize the growth conditions and concentra-
tion for IPTG induction had shown that a signi¢cant fraction
of the TrxCFTR(TM3^4) fusion protein is found in inclusion
bodies when the protein is induced for 4 h with relatively high
concentrations of IPTG (1^5 mM). The positive e¡ect of re-
duced induction temperature for the production of soluble
proteins has been observed, and indeed, we found that
TrxCFTR(TM3^4) fusion proteins induced at lower temper-
ature are considerably more soluble; as shown in Fig. 4,
greater than 80% of the fusion protein appeared in the insolu-
ble fraction at 37‡C while less than 50% was insoluble at
25‡C. Using a shorter induction time (2 h), along with a lower
level of IPTG (0.1 mM), the fusion proteins produced from
the plasmid were almost entirely soluble at 25‡C (Fig. 4B).
The solubility was enhanced by the presence of detergent
(0.1% Triton X-100) and NaCl (up to 0.5 M) in the lysis
bu¡er (data not shown). Increasing salt concentration up to
1 M appeared to have little or no further e¡ect on solubility.
3.3. Puri¢cation of fusion proteins
Fig. 5 shows a Coomassie Blue stained gel (A) and an
immunoblot (B) of the puri¢ed TrxCFTR(TM3^4) fusion pro-
tein eluted from a nickel a⁄nity column. All of the Triton X-
100-solubilized TrxCFTR(TM3^4) protein became bound to
the nickel chelate His-bind resin when chromatographed in
bu¡er A (lane 2). Essentially all of the bound fusion protein
could be eluted at 400 mM imidazole to give a single band
corresponding to the expected molecular mass of approxi-
mately 24 kDa on SDS-PAGE. No contaminating protein(s)
could be detected by immunoblotting (Fig. 5B). When 0.1%
Triton-100 was added into the elution bu¡er, the resulting
proteins were greater than 95% pure, and stable during dial-
ysis against 50 mM Tris-HCl, pH 8.0, 150 mM NaCl. In
general, we have been able to produce 15^20 mg of puri¢ed
fusion protein in soluble fractions from 1 l of LB culture. The
puri¢ed fusion proteins (with or without dithiothreitol) are
very stable and concentrated solutions (1 mg/ml) do not pre-
cipitate during storage at 4‡C for several weeks.
3.4. Proteolysis of the fusion protein
When the fusion protein was cleaved with 5% (w/w) throm-
bin at pH 8.0, 37‡C, near the optimal cleavage conditions of
the protease, 90% of the fusion protein was proteolyzed in less
than 3 h. However, more than 80% of the liberated
CFTR(TM3^4) appeared to have been degraded. Because of
this secondary proteolysis, studies were performed to develop
conditions for a more selective cleavage of the linker, but with
less internal processing. Lowering both pH and the temper-
ature gave slower, but very selective cleavage. From these
results, more suitable conditions for cleavage could be
evolved, viz. pH 7.2 and 22‡C. Using these parameters, the
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Fig. 3. Accumulation of TrxCFTR(TM3^4) in bacteria. E. coli
(BL21) strain carrying the p32CFTM-P3 construct was induced for
expression. A: Total cell extracts electrophoresed on SDS-PAGE.
Proteins were stained with Coomassie Blue R-250. Lanes 1 and 4:
uninduced; lanes 2 and 5: induced with IPTG at 37‡C; lanes 3 and
6: induced with IPTG at 25‡C. B: Western blot using a monoclonal
antibody against thioredoxin. Lanes correspond to those given in A.
Fig. 4. A: SDS-PAGE showing distribution of expressed
TrxCFTR(TM3^4) fusion protein between supernatant (SOL) and
inclusion bodies (INS). I, induced (with IPTG) for 3 h, UI, unin-
duced. Induction temperatures are indicated. B: SDS-PAGE show-
ing optimized solubilization of TrxCFTR(TM3^4), using 2 h induc-
tion at 25‡C.
Fig. 5. Puri¢cation of TrxCFTR(TM3^4) by a⁄nity chromatogra-
phy. A: The soluble fraction (shown in Fig. 4B) applied to a nickel
chelate a⁄nity column (lane 1). Flow-through at 5 mM imidazole
(lane 2). The column was washed with lysis bu¡er containing in-
creasing concentrations (5 mM to 500 mM) of imidazole; the fusion
protein was eluted at 400 mM imidazole (lane 3). B: Western blot
using an antibody to thioredoxin. Lane numbers correspond to
those given in A.
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fusion protein was completely digested by thrombin in 3 h.
Fig. 6 presents the pattern of thrombin cleavage, where the
two main fragments were found to correspond to the expected
molecular masses of thioredoxin and the CFTR(TM3^4) poly-
peptide, respectively.
3.5. Preparative scale recovery of thrombin-cleaved
CFTR(TM3^4) segments
The thrombin cleavage reaction was scaled up to approach
the milligram quantities of the CFTR(TM3^4) polypeptide
required for detailed structural characterization. When the
digestion was completed, as evidenced by the disappearance
of the 24 kDa band in the digested samples on the SDS-
PAGE, the released CFTR(TM3^4) (containing an S-tag (15
aa); see Fig. 2) could be separated from by-products by var-
ious methods. In an initial series of experiments, the thio-resin
column unexpectedly failed to retain the thioredoxin fusion
partner, with both CFTR(TM3^4) and thioredoxin being re-
moved at the same time; the CFTR(TM3^4) polypeptide was
eventually puri¢ed by a⁄nity chromatography on S-protein
agarose. However, using an S-protein HRP conjugate, a single
band was detected as monitored by SDS-PAGE and Western
blotting. Following puri¢cation by the latter method, the S-
resin a⁄nity chromatography yielded approximately 70% re-
covery (based on molar ratio vs. fusion protein input) of
thrombin-released CFTR(TM3^4). In a further protocol,
SDS-PAGE gel puri¢cation gave the CFTR(TM3^4) polypep-
tide in ca. 20% yield.
3.6. Conformational properties of puri¢ed proteins
As established for several membrane proteins, the trans-
membrane domains of CFTR are expected to be K-helical
[21]. To obtain direct experimental evidence of such helical
character, CD spectroscopy ^ which is responsive to the con-
tribution of various protein secondary structural elements ^
was used to evaluate the overall conformation of puri¢ed
CFTR-derived proteins. Conformations of the unmodi¢ed
vector protein (Trx-S-tag), TrxCFTR(TM3^4), and free
CFTR(TM3^4) were ¢rst examined in aqueous bu¡er (con-
taining 0.05% Triton X-100) (Fig. 7). Both the vector protein
and thrombin-cleaved CFTR(TM3^4) polypeptide display CD
spectra in aqueous bu¡er broadly characteristic of partial
K-helical structures (and with coincidentally similar negative
ellipticity). The spectrum of TrxCFTR(TM3^4) fusion protein
displays considerable K-helical conformation with pronounced
double minima near 219 and 210 nm. As the separation of
these two minima is relatively narrow (vV= 9 nm) vs. typical
pure K-helical spectra (vV= 14 nm) [22], the spectrum is in-
dicative of the presence of additional ordered structures, pre-
sumably the L-sheets which are known to arise in the tertiary
structure of thioredoxin [23]. The latter results do attest to the
correct folding of (at least) the thioredoxin portion of the
fusion protein.
Importantly, the extent of helical structure in the
CFTR(TM3^4) polypeptide is enhanced by the addition of
10 mM LPC micelles (Fig. 8b). Since such helix promotion
is not detected in the Trx-S-tag vector protein (which lacks
CFTR segments) (Fig. 8a), the increase in K-helical content is
likely contributed by micelle-protein interactions speci¢c to
the putative TM segments of CFTR(TM3^4). Table 1 presents
the K-helical content of CFTR(TM3^4) polypeptide in a vari-
ety of environments. The largest helical content, calculated as
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Fig. 6. Thrombin cleavage of TrxCFTR(TM3^4) fusion protein and
recovery of CFTR (TM3^4) polypeptide. A: Lane 1, control. Fu-
sion protein incubated with cleavage bu¡er (3 h) without thrombin.
Lane 2, fusion protein treated with thrombin at a protease-to-fusion
protein ratio of 1:100 at ambient temperature for 3 h. Lane 3, £ow-
through of the cleavage mixture applied to S-protein agarose col-
umn, showing released thioredoxin. Lane 4, released CFTR(TM3^
4), eluted from S-protein agarose column by 4 M urea. Following
electrophoresis (16% SDS tricine polyacrylamide gel), the gel was
stained with silver nitrate. B: The identity of the CFTR(TM3^4)
polypeptide (lane 4 in A) con¢rmed by Western blotting using an
antibody against the S-tag peptide sequence.
Fig. 7. Circular dichroism spectra of (a) vector (p32) protein (Trx-S-
tag); (b) CFTR(TM3^4); and (c) TrxCFTR(TM3^4). Spectra are re-
corded in 50 mM Tris-HCl, pH 7.2, 100 mM HCl, and 0.05% Tri-
ton X-100. Trx, His-tagged thioredoxin, with the His-tag attached
to the protein C-terminus. See Section 2 for further details of CD
spectroscopic measurements.
Fig. 8. Circular dichroism spectra showing addition of 10 mM lyso-
phosphatidylcholine micelles (above the critical micelle concentra-
tion) to (a) vector (p32) protein; and (b) thrombin-released
CFTR(TM3^4) polypeptide. CD spectra were recorded as described
under Fig. 7; see also Table 1.
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ca. 60% for the thrombin-released CFTR(TM3^4) polypep-
tide, is induced by negatively-charged lyso-phosphatidylglyc-
erol (LPG) micelles. Considering the presumed aqueous-based
location for the polar S-tag and His-tag residues of
CFTR(TM3^4) in the presence of micelles, this helical content
of 60% is representative of a nearly full helical conformation
for the two e¡ective CFTR TM(3^4) segments.
3.7. Conclusion
We have successfully expressed the Trx-CFTR(TM3^4) fu-
sion protein in high yield in soluble form. Expressed fusion
proteins could be readily puri¢ed by nickel chelate a⁄nity
chromatography. A 1 l culture of BL21(DE3) E. coli trans-
formed with the recombinants expressed 15^20 mg of puri¢ed
soluble fusion protein. Thrombin cleavage was e¡ective in the
quantitative removal of the thioredoxin fusion partner from
CFTR(TM3^4) polypeptide. Undesirable cleavage of the
polypeptide was avoided by optimization of the enzyme diges-
tion conditions. Availability of this expression vector could
facilitate production of TM domains of CFTR both for struc-
tural/functional, as well as therapeutic, studies.
The gross appearance of CFTR(TM3^4) CD spectra sug-
gests that the polypeptide can readily adopt an K-helical con-
formation. CFTR(TM3^4) was shown to be incorporated into
phospholipid micelles, and, in preliminary results, inserted
into phospholipid vesicle bilayers (data not shown). Although
the CFTR(TM3^4) polypeptide shows a pronounced tendency
to adopt signi¢cantly folded structure, it remains to be estab-
lished whether the two e¡ective TM segments of CFTR(TM3^
4) are surrounded by lipids in an essentially linear ‘rod-like’
form, or whether they have become folded into a ‘helical hair-
pin’, where the native-like contacts between TM segments 3^4
^ as they occur within the intact CFTR membrane domain ^
have been restored. No concentration dependence of helicity
was observed at polypeptide concentrations between 5 WM to
25 WM ^ an indication that the K-helical structure formed is
intramolecular, rather than intermolecular as has been ob-
served in some model systems (28). Subsequent NMR analysis
of CFTR(TM3^4) is expected to provide further insights into
the topography of the polypeptide within the membrane en-
vironment.
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Table 1
Helical content (K%) of thrombin-released CFTR(TM3^4) polypep-
tide in various environments
Environment 3[a]222a K %b 3[a]208 K %c
Waterd 11000 29 13000 31
SDSe 14800 39 15600 40
LPC 16000 42 17475 46
LPG 18000 47 21740 61
aMean residue ellipticity, expressed in deg cm2 dmol31.
bCalculated by the method of Chen et al. [22].
cCalculated by the method of Green¢eld and Fasman [24].
dPeptide concentration, 4.9 WM; aqueous bu¡er, 50 mM Tris-HCl,
150 mM NaCl, pH 8.
eMicelle concentration, 10 mM.
S. Peng et al./FEBS Letters 431 (1998) 29^33 33
